SC
AXSM icon

Steven Cohen’s Axsome Therapeutics AXSM Stock Holding History

Steven Cohen’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102M Sell
416,516
-8,234
-2% -$1.79M 0.11% 199
2026
Q1 		$71.8M Buy
424,750
+406,751
+2,260% +$70.3M 0.09% 250
2025
Q4 		$3.29M Sell
17,999
-715
-4% -$99.8K ﹤0.01% 2137
2025
Q3 		$2.27M Sell
18,714
-332,259
-95% -$37.4M ﹤0.01% 1387
2025
Q2 		$36.6M Buy
350,973
+224,780
+178% +$23.8M 0.07% 313
2025
Q1 		$14.7M Sell
126,193
-58,945
-32% -$6.72M 0.03% 539
2024
Q4 		$15.7M Sell
185,138
-357,482
-66% -$32.9M 0.03% 543
2024
Q3 		$48.8M Buy
542,620
+63,576
+13% +$5.55M 0.12% 195
2024
Q2 		$38.6M Buy
479,044
+100,180
+26% +$7.42M 0.1% 266
2024
Q1 		$30.2M Sell
378,864
-458,337
-55% -$38.5M 0.07% 322
2023
Q4 		$66.6M Buy
837,201
+305,264
+57% +$20.4M 0.16% 162
2023
Q3 		$37.2M Buy
531,937
+63,934
+14% +$4.78M 0.11% 239
2023
Q2 		$33.6M Sell
468,003
-701,824
-60% -$51.8M 0.1% 255
2023
Q1 		$72.2M Buy
1,169,827
+519,762
+80% +$34.1M 0.22% 114
2022
Q4 		$50.1M Buy
650,065
+32,165
+5% +$1.92M 0.17% 152
2022
Q3 		$27.6M Buy
617,900
+576,125
+1,379% +$28.8M 0.11% 247
2022
Q2 		$1.6M Buy
+41,775
New +$1.32M 0.01% 986
2021
Q2 		– Sell
-42,300
Closed -$2.4M – 963
2021
Q1 		$2.4M Sell
42,300
-35,200
-45% -$2.48M 0.01% 708
2020
Q4 		$6.31M Sell
77,500
-13,157
-15% -$984K 0.03% 543
2020
Q3 		$6.46M Sell
90,657
-168,740
-65% -$13.1M 0.03% 506
2020
Q2 		$21.3M Sell
259,397
-424,857
-62% -$32.7M 0.14% 207
2020
Q1 		$40.3M Buy
+684,254
New +$55.8M 0.33% 78
2019
Q4 		– Sell
-160,000
Closed -$3.24M – 960
2019
Q3 		$3.24M Buy
+160,000
New +$4.11M 0.02% 526
2019
Q1 		– Sell
-250,000
Closed -$705K – 1015
2018
Q4 		$705K Buy
+250,000
New +$823K ﹤0.01% 849

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steven Cohen's AXSM Position: Q2 2026 in Review

Steven Cohen reduced its Axsome Therapeutics (AXSM) stake by 1.9% in Q2 2026, selling an estimated $1.79M and leaving 416,516 shares worth $102M. The position accounts for 0.11% of the portfolio, ranked #199.

Steven Cohen first reported a position in AXSM in Q4 2018 and has held it in 24 quarters since. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Steven Cohen held 416,516 shares of Axsome Therapeutics worth $102M as of Q2 2026.
  • Steven Cohen sold 8,234 Axsome Therapeutics shares in Q2 2026, an estimated $1.79M.
  • Axsome Therapeutics made up 0.11% of Steven Cohen's portfolio in Q2 2026, its #199 holding.
  • Steven Cohen first reported a position in Axsome Therapeutics in Q4 2018 and has held it in 24 quarters since.
  • 502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.